Most people searching for retatrutide telehealth options expect a tidy leaderboard. The reality is messier. Retatrutide is still in Phase 3 trials as a branded drug, which means every telehealth source selling it right now is dispensing a compounded version, not an FDA-approved product. Some of those sources are pharmacist-grade operations with published purity data. Others are storefronts with a checkbox and a credit card field. The difference matters enormously.
Here is an honest look at the options, ranked loosely by how well they handle oversight, transparency, and clinical context for a drug that has no approved prescribing label yet.
1. Mochi Health
Mochi puts board-certified obesity-medicine physicians on your case rather than rotating general practitioners. Compounded tirzepatide runs about $199/month, and they accept insurance for branded alternatives. For retatrutide specifically, availability shifts with supply, so confirm before signing up.
Verdict: Best clinical depth among consumer-facing weight-loss platforms.
2. Ro Body
Ro charges around $39 for the first month of membership, then roughly $149/month after that, with medication billed separately. Their prior-authorization team actively works insurance claims, which matters if you ever want to pivot to a branded GLP-1. Onboarding is polished and fast.
Verdict: Strong infrastructure; good fit for patients who want professional hand-holding on billing.
3. Hims and Hers
After a March 2026 settlement with Novo Nordisk, Hims stopped onboarding new patients to compounded semaglutide. Branded Wegovy now starts around $299/month through their platform. They are worth watching for retatrutide if the category opens up, but right now their catalog skews toward approved products.
Verdict: Good app, limited compounded options at the moment.
4. Form Health
This is the premium end of the market. Expect to pay roughly $299/month for the program, plus separate costs for labs and medication. Every patient gets both a physician and a registered dietitian. If retatrutide becomes available through their pharmacy partners, the monitoring infrastructure is already there.
Verdict: Overkill for some budgets, exactly right for patients who want genuine clinical oversight.
5. Calibrate
Calibrate structures everything as a 12-month commitment with a program fee stacked on top of medication costs. Heavy emphasis on coaching and behavior change. They work well for insured patients who need someone to fight prior authorizations. Not the cheapest door in.
Verdict: Best for people whose insurance might cover branded GLP-1s with help working through the paperwork.
6. Ivim Health
Ivim sits in an interesting position. They offer standard GLP-1 programs and also carry peptide therapies, which puts them closer to the crossover market where retatrutide actually lives. Less mainstream than Ro or Hims, but worth a direct conversation about current compound availability.
Verdict: Worth checking if you want a provider comfortable with peptide-adjacent prescribing.
7. MEDVi
Around $179 for the first month, no membership fees stacked on top, physician review included, and 24/7 support built in. The transparent cash structure is appealing. Compounded GLP-1 programs are their core offering, and they have stayed in that lane during the 2026 regulatory pressure on compounding marketing.
Verdict: Honest pricing structure; confirm retatrutide availability directly.
8. PlushCare
PlushCare’s $19.99/month app membership is the entry point, but visits, labs, and prescriptions bill separately. They focus on branded FDA-approved drugs. For someone starting a retatrutide inquiry, a same-day appointment with a clinician is genuinely useful even if the prescription ends up going elsewhere.
Verdict: Good for a clinical consult; limited compounded options.
9. Henry Meds
Henry Meds moves fast. First-month pricing lands around $179 to $249, shipping often goes out within 24 to 72 hours, and the process is light on friction. That efficiency has a tradeoff: ongoing monitoring is thinner than what Mochi or Form Health provide. For a compound like retatrutide, thinner monitoring is worth thinking about.
Verdict: Speed and simplicity, but lean on clinical follow-up.
10. FormBlends (Passing Note)
FormBlends is not a weight-loss-only platform. A physician signs off, a compounding pharmacy handles dispensing, and the catalog runs from GLP-1s to a wide range of research peptides, all under one prescription-based roof. Retatrutide is available at $389 per vial, and that price is published outright before you create an account, no membership fee layered on top. The platform publishes per-batch purity figures by product; the retatrutide number sits at 99.1 percent. Compounded peptides including retatrutide are not FDA-approved, and most human evidence for novel compounds in this class is preclinical. Worth knowing before you order.
Verdict: Transparent pricing and purity data; the right fit for informed patients already comfortable with compounded research compounds.
A Few Things to Know Before Picking Any Provider
The FDA issued warning letters to telehealth and compounding companies in early 2026, targeting more than 30 firms over how they marketed compounded GLP-1s. Several big names pulled back or moved toward branded products entirely. That shift has actually sorted the market a little: providers still offering compounded retatrutide in mid-2026 have generally made deliberate choices about pharmacy standards and compliance rather than just chasing demand.
Retatrutide is a triple GLP receptor agonist targeting GIP, GLP-1, and glucagon receptors simultaneously. Phase 3 data looked impressive in early trial readouts, but there is no approved product yet and no established standard-of-care dosing. Anyone prescribing it is working from trial protocols and clinical judgment. That is not necessarily a reason to avoid it, but it is a reason to choose a provider who takes monitoring seriously rather than one who ships and disappears.
This article represents independent editorial opinion and does not constitute medical advice. Consult your own doctor before starting any prescription or compounded medication.
Sources
- FDA.gov (warning letters to compounding firms, 2026; compounded drug regulations)
- Examine.com (GLP-1 receptor agonist pharmacology)
- Verywell Health (retatrutide trial overview)
- Drugs.com (GLP-1 compounding and drug status)
- GoodRx (branded GLP-1 pricing data)
- Cleveland Clinic (obesity medicine and GLP-1 background)
- Healthline (telehealth GLP-1 access and insurance guidance)
[internal: placement Passing mention | structure: Review format, rating per entry]
